TRAM2-AS1: A Potential Drug Target and Biomarker (G401264)

Target Name: TRAM2-AS1

NCBI ID: G401264

TRAM2-AS1

Other Name(s): TRAM2 antisense RNA 1 (head to head), transcript variant 2 | TRAM2 antisense RNA 1 (head to head) | TRAM2 antisense RNA 1 (head to head), transcript variant 1

TRAM2-AS1: A Potential Drug Target and Biomarker

TRAM2-AS1, a transcribed RNA molecule, has been identified as a potential drug target and biomarker in various diseases, including cancer. Its unique structure and function have made it an attractive target for drug development, and its expression has been confirmed in various tissues and conditions.

TRAM2-AS1 is a non-coding RNA molecule that is expressed in various tissues and organs, including the brain, heart, liver, and muscle. Its function is not well understood, but research has shown that it plays a role in the regulation of various cellular processes, including cell growth, apoptosis, and inflammation.

One of the most promising aspects of TRAM2-AS1 is its potential as a drug target. Its unique structure and function make it an attractive target for small molecules, antibodies, or other therapeutic agents that can modulate its expression or activity.

TRAM2-AS1 has been shown to play a role in the regulation of cell apoptosis, which is the process by which cells undergo programmed cell death. In cancer cells, abnormal cell apoptosis can contribute to the development and progression of cancer. Therefore, targeting TRAM2-AS1 with drugs that can induce or inhibit its expression could be a promising strategy for cancer treatment.

Another potential use of TRAM2-AS1 as a drug target is its role in inflammation.TRAM2-AS1 has been shown to be involved in the regulation of various inflammatory responses, including the regulation of cytokine production and the modulation of immune cell function. Therefore, targeting TRAM2-AS1 with drugs that can modulate its expression or activity could be a promising strategy for the treatment of inflammatory diseases.

In addition to its potential as a drug target, TRAM2-AS1 has also been identified as a potential biomarker. Its unique expression pattern and function make it an attractive candidate for use as a diagnostic or predictive marker for various diseases, including cancer.

TRAM2-AS1 has been shown to be expressed in various tissues and conditions, including the brain, heart, liver, and muscle. Its expression has also been confirmed in various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. Therefore, tracking the expression of TRAM2-AS1 could be a useful diagnostic or predictive marker for these diseases.

Furthermore, TRAM2-AS1 has been shown to play a role in the regulation of cellular processes that are important for human health. Its expression has been associated with the regulation of cell growth, apoptosis, and inflammation, all of which are important for the proper functioning of cells and the maintenance of human health.

In conclusion, TRAM2-AS1 is a promising drug target and biomarker with unique structure and function. Its potential as a drug target for cancer and its potential as a biomarker for various diseases make it an attractive target for further research and development. Further studies are needed to fully understand its role in cellular processes and its potential as a therapeutic agent.

Protein Name: TRAM2 Antisense RNA 1 (head To Head)

The "TRAM2-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRAM2-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets